Jae‐Cheol Jo

Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study

Summary Relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death‐ligand 1 (PD‐L1), was evaluated in adults with R/R ENKTL in a phase 2, open‐label study (NCT04414163). Danburstot...